Skip to main content

Advertisement

SpringerLink
Log in

Cerebrotendinous Xanthomatosis: The Effectiveness of High-Dose Piracetam for the Treatment of Cerebellar and Sensorial Ataxia

  • Case Report
  • Published:
The Cerebellum Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266:7779–83.

    CAS  PubMed  Google Scholar 

  2. Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med. 2004;27:42–50.

    CAS  PubMed  Google Scholar 

  3. Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. In: Pagon RA, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. Gene reviews. Seattle, WA: University of Washington; 2013. p. 1993–2003.

    Google Scholar 

  4. Barkhof F, Verrips A, Wesseling P, van Der Knaap MS, van Engelen BG, Gabreëls FJ, et al. Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology. 2000;217:869–76.

    Article  CAS  PubMed  Google Scholar 

  5. Salen G, Berginer V, Shore V, Horak I, Horak E, Tint GS. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. N Engl J Med. 1987;316:1233–8.

    Article  CAS  PubMed  Google Scholar 

  6. Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984;311:1649–52.

    Article  CAS  PubMed  Google Scholar 

  7. Mignarri A, Dotti MT, Del Puppo M, Gallus GN, Giorgio A, Cerase A, et al. Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation: six-year MRI follow-up. Neuroradiology. 2012;54:649–51.

    Article  PubMed  Google Scholar 

  8. Verrips A, Wevers RA, Van Engelen BG, Keyser A, Wolthers BG, Barkhof F, et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism. 1999;48:233–8.

    Article  CAS  PubMed  Google Scholar 

  9. Ince Gunal D, Agan K, Afsar N, Borucu D, Us O. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients. J Clin Pharm Ther. 2008;33:175–8.

    Article  CAS  PubMed  Google Scholar 

  10. Vural M, Ozekmekci S, Apaydin H, Altinel A. High-dose piracetam is effective on cerebellar ataxia in patients with cerebellar cortical atrophy. Mov Disord. 2003;18:457–9.

    Article  PubMed  Google Scholar 

  11. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11:169–82.

    Article  CAS  PubMed  Google Scholar 

  12. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287–312.

    Article  CAS  PubMed  Google Scholar 

  13. Marisco PC, Carvalho FB, Rosa MM, Girardi BA, Gutierres JM, Jaques JA, et al. Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5′-nucleotidase and adenosine deaminase activities. Neurochem Res. 2013;38:1704–14.

    Article  CAS  PubMed  Google Scholar 

  14. Obeso JA. Therapy of myoclonus. Clin Neurosci. 1995–1996;3:253–7.

    Google Scholar 

  15. De Rosa A, Striano P, Barbieri F, de Falco A, Rinaldi C, Tucci T, et al. Suppression of myoclonus in SCA2 by piracetam. Mov Disord. 2006;21:116–8.

    Article  PubMed  Google Scholar 

  16. Orsucci D, Ienco EC, Rocchi A, Siciliano G, Mancuso M, Bonuccelli U. Levetiracetam-responsive myoclonus in spinocerebellar ataxia type 15. Mov Disord. 2013;28:1465.

    CAS  PubMed  Google Scholar 

  17. Saponara R, Greco S, Proto G, Trubia T, Domina E. Levetiracetam improves intention tremor in fragile x-associated tremor/ataxia syndrome. Clin Neuropharmacol. 2009;32:53–4.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

None of the authors have received financial support or funding over the preceding 12 months, regardless of the relationship to the current manuscript.

Author information

Authors and Affiliations

  1. Department of Neurology, Cerrahpasa School of Medicine, Istanbul University, K.M. Pasa, 34098, Istanbul, Turkey

    Ugur Uygunoglu, Aysegul Gunduz, Sukriye F Menku, Basak Yilmaz, Cengiz Yalcinkaya, Sabahattin Saip & Hulya Apaydin

  2. Department of Internal Medicine, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey

    Esra Hatipoglu

Authors
  1. Ugur Uygunoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aysegul Gunduz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sukriye F Menku
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Basak Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Esra Hatipoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cengiz Yalcinkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabahattin Saip
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hulya Apaydin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aysegul Gunduz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uygunoglu, U., Gunduz, A., Menku, S.F. et al. Cerebrotendinous Xanthomatosis: The Effectiveness of High-Dose Piracetam for the Treatment of Cerebellar and Sensorial Ataxia. Cerebellum 13, 787–790 (2014). https://doi.org/10.1007/s12311-014-0587-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12311-014-0587-y

Keywords

Search

Navigation